Longhorn Vaccines

Longhorn Vaccines & Diagnostics is a private, integrated biotech company with a dual focus on diagnostics and vaccine development. Its commercial foundation is built on PrimeStore MTM, a patented molecular transport medium that inactivates pathogens and preserves nucleic acids, which gained significant utility during the COVID-19 pandemic. The company's R&D pipeline is centered on a composite peptide vaccine platform, with lead candidate LHNVD-303 targeting sepsis from bacterial infections and antimicrobial-resistant tuberculosis, and LHNVD-501, a monoclonal antibody for preventing bacterial infections and sepsis. Longhorn operates as a small, agile organization leveraging over 35 years of collective biotech experience to address global public health threats.

Composite peptide vaccine platform targeting conserved bacterial epitopes; and patented Molecular Transport Media (MTM) platform for pathogen inactivation and nucleic acid stabilization in diagnostic sample collection.

In diagnostics, Longhorn competes with larger sample collection media companies, though its PrimeStore MTM's specific pathogen inactivation claims are a differentiator. In the sepsis/AMR vaccine space, it faces competition from numerous biopharma companies developing immunotherapies and vaccines, but its composite peptide approach targeting conserved epitopes is a novel strategy.